RapidAI Overview

  • Founded
  • 2011

  • Status
  • Private

  • Employees
  • 189

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $25M

  • Investors
  • 2

RapidAI General Information


Operator of neuroimaging platform intended to create high-quality images from non-contrast CT and MRI scans. The company's platform provides viewing, processing, and analysis of brain images and also empowers clinicians to make accurate diagnostic and treatment decisions for stroke patients, enabling doctors to get additional assistance while treating strokes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Decision/Risk Analysis
Primary Office
  • 1120 Washington Avenue
  • Suite 200
  • Golden, CO 80401
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RapidAI Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series B) 16-Sep-2020 $25M 0000 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 10-Jan-2014 000 000 0000 Completed Generating Revenue
To view RapidAI’s complete valuation and funding history, request access »

RapidAI Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 000,000 00.000000 000.00 000.00 00 000.00 0.000
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view RapidAI’s complete cap table history, request access »

RapidAI Patents

RapidAI Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230036757-A1 Concurrent display of hemodynamic parameters and damaged brain tissue Pending 28-Jul-2021 000000000
US-11295448-B1 Concurrent display of hemodynamic parameters and damaged brain tissue Active 28-Jul-2021 000000000 0
US-11348241-B2 Identifying vessel occlusions using spatial patterns Active 14-Oct-2020 0000000000 0
US-20220114726-A1 Identifying vessel occlusions using spatial patterns Active 14-Oct-2020 0000000000
EP-4142580-A1 Assessment of facial paralysis and gaze deviation Pending 29-Apr-2020 A61B5/163
To view RapidAI’s complete patent history, request access »

RapidAI Executive Team (12)

Name Title Board Seat Contact Info
Rekha Kapania Chief Financial Officer
Gregory Albers MD Co-Founder, Scientific Lead & Chairman
Amit Phadnis Chief Innovation and Technology Officer
Roland Bammer Ph.D Co-Founder, Technical Lead and Board Member
Diane Merrick Senior Vice President, Marketing
You’re viewing 5 of 12 executive team members. Get the full list »

RapidAI Board Members (9)

Name Representing Role Since
Erol Dervis Lennertz & Co. Board Member 000 0000
Gregory Albers MD RapidAI Co-Founder, Scientific Lead & Chairman 000 0000
Hadi Saleh Ph.D Self Board Observer 000 0000
John Drew Self Board Member 000 0000
Karim Karti Self Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

RapidAI Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RapidAI Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Lennertz & Co. Family Office Minority 000 0000 000000 0
Listwin Ventures Venture Capital Minority 000 0000 000000 0
To view RapidAI’s complete investors history, request access »

RapidAI Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 09-Jun-2020 0000000000 Other Devices and Supplies 000000 00
To view RapidAI’s complete acquisitions history, request access »